AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
MWN-AI** Summary
AtriCure, Inc. (Nasdaq: ATRC), a leader in innovations for surgical treatments of atrial fibrillation (Afib), has announced the successful enrollment and treatment of its first patient in the BoxX-NoAF clinical trial. This trial aims to assess the safety and effectiveness of AtriCure's Isolator® Synergy™ EnCompass® clamp and the AtriClip® Left Atrial Appendage Exclusion System in preventing new-onset Afib in patients undergoing cardiac surgery. The procedure was performed by Dr. Anthony Rongione at the Orlando Health Heart and Vascular Institute.
Post-operative Afib (POAF) is a prevalent complication in cardiac surgery, affecting up to 50% of patients, leading to increased mortality, morbidity, and healthcare costs. The BoxX-NoAF trial intends to explore a novel approach, combining box lesion creation with left atrial appendage exclusion, to mitigate the incidence of POAF. The study represents a significant step as it is a multicenter, randomized, FDA-approved trial involving 960 subjects across 75 sites globally, which aims to redefine treatment protocols for high-risk patients.
AtriCure’s CEO, Michael Carrel, expressed the company's commitment to enhancing patient outcomes through advanced surgical techniques. The trial is anticipated to yield impactful results that could position AtriCure for expanded regulatory approvals, thereby establishing its devices as critical interventions in minimizing Afib-related complications post-surgery.
Dr. Edward G. Soltesz emphasized the importance of addressing POAF, identifying the potential of the BoxX procedure to significantly improve patient care. If successful, this trial could enhance AtriCure's market presence and affirm the efficacy of their devices in reducing the prevalence of Afib-related complications on a broader scale.
For further details, the BoxX-NoAF trial information is available at clinicaltrials.gov.
MWN-AI** Analysis
AtriCure, Inc. (Nasdaq: ATRC) recently made headlines with the commencement of the BoxX-NoAF clinical trial, focusing on reducing new-onset atrial fibrillation (Afib) in cardiac surgery patients. This development highlights AtriCure's commitment to not only addressing a significant complication related to cardiac procedures but also potentially expanding their market presence with HD-approved technologies.
The BoxX-NoAF trial aims to assess the safety and effectiveness of the AtriCure Isolator® Synergy™ EnCompass® clamp and AtriClip® Left Atrial Appendage Exclusion System. With postoperative Afib affecting nearly half of cardiac surgery patients, successful trial results could translate into compelling market opportunities. If the devices prove effective, AtriCure may see an uptick in hospital adoption, which would bolster revenues and market share.
Investors should closely monitor the trial's progress, as positive outcomes could lead to expanded FDA labeling and increased sales potential. Moreover, AtriCure's existing product line, which has already established a strong foothold globally, stands to benefit significantly from enhanced clinical backing. A successful trial could ultimately result in broadened guidelines for Afib management in surgical patients, reinforcing AtriCure's leadership in this niche.
However, investors should be mindful of risks outlined in the company’s forward-looking statements. Challenges include potential delays in regulatory approvals or reimbursement issues, which may affect the adoption of their new therapies.
In conclusion, with the BoxX-NoAF trial underway, AtriCure represents an intriguing opportunity for investors who are willing to take on some risk. Given the high prevalence of Afib and the growing need for effective treatment options, a favorable outcome in the trial could catalyze significant growth for AtriCure moving forward. Keeping an eye on trial milestones and broader market trends will be essential for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Trial will evaluate the safety and effectiveness of the AtriCure Isolator ® Synergy™ EnCompass ® clamp and AtriClip ® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset atrial fibrillation in cardiac surgery patients
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was enrolled and treated in the Box Lesion Creation with Left Atrial Appendage E x clusion to Reduce the Occurrence of N ew- o nset A trial F ibrillation ( BoxX-NoAF ) clinical trial (NCT06989775). The first patient was treated by Dr. Anthony Rongione, Cardiothoracic Surgeon at Orlando Health Heart and Vascular Institute in Orlando, Florida.
New onset or post-operative Afib (POAF) is the most common complication following cardiac surgery, occurring in as many as 50% of patients 1,2 presenting immediately or in the months following surgery. These arrhythmias are associated with increased mortality, morbidity, cerebrovascular accidents, Afib recurrence, hospital length of stay, and total hospital costs. BoxX-NoAF is a prospective, multicenter, randomized, FDA-approved investigational device exemption (IDE) clinical trial of up to 960 subjects at up to 75 sites worldwide. This seminal trial will ultimately define clinical practice and treatment guidelines for reducing the occurrence of POAF and longer-term clinical Afib in elevated risk cardiac surgery patients.
“The BoxX-NoAF trial, together with our LeAAPS trial that completed enrollment in July 2025, reflects AtriCure’s vision to advance standards of care by expanding the benefits of surgical ablation and LAA exclusion to a broader population of cardiac surgery patients,” said Michael Carrel, President and Chief Executive Officer. “We expect results of these trials to demonstrate that use of AtriCure devices can safely and effectively improve outcomes for cardiac surgery patients worldwide by reducing the prevalence of new-onset Afib, stroke, and systemic embolization. These studies reinforce our commitment to pioneering clinical science to expand our addressable markets.”
“POAF remains one of the most challenging complications for patients who have undergone cardiac surgery, undermining patient recovery and consuming significant hospital resources,” said Edward G. Soltesz, MD, MPH, Cleveland Clinic cardiovascular and thoracic surgeon. “We believe the BoxX procedure, combining a box lesion and LAA exclusion, could meaningfully lower the occurrence of new-onset Afib and significantly improve the quality of care for these patients.”
The BoxX-NoAF trial is the first randomized controlled trial designed to demonstrate superiority of concomitant surgical ablation with LAA management for reducing the occurrence of new-onset Afib POAF compared to no treatment. If successful, trial results would position AtriCure to pursue expanded labeling for the EnCompass clamp and AtriClip systems when used together in a BoxX procedure, and the only FDA-approved devices for the prevention of post-operative and longer-term clinical Afib. For more information about the BoxX-NoAF trial, please visit: clinicaltrials.gov/study/NCT06989775 .
1.Raiten et al, Atrial Fibrillation After Cardiac Surgery: Clinical update on the Mechanisms and Prophylactic Strategies, Journal of Cardiovascular and Thoracic Anesthesia, Vo 26. No 3, (June) 2015, pp 808-816.
2.Lomivorotov et al, New-onset Atrial Fibrillation After Cardiac Surgery: Pathophysiology, Prophylaxis, and Treatment, Journal of Cardiovascular and Thoracic Anesthesia, Vo 30. No 1, (February) 2016, pp 208-216.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent and long-standing persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.
Forward-Looking Statements
Certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Actual results may differ materially from those projected by any forward-looking statements. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data, including data that does not demonstrate sufficient safety and efficacy with respect to our products; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; the impact of tariffs or other restrictive trade measures; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 14, 2025, and our quarterly reports on Form 10-Q. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251028285132/en/
Angie Wirick
Investor Relations
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Valerie Storch-Willhaus
Media Relations
Vice President, Corporate Marketing & Communications
(612) 605-3311
vstorch-willhaus@atricure.com
FAQ**
How might the results of the BoxX-NoAF trial impact AtriCure Inc. (Nasdaq: ATRC) in terms of market positioning and potential expanded labeling for its EnCompass and AtriClip devices?
What are the key risks highlighted by AtriCure Inc. (ATRC) that could affect the outcome of the BoxX-NoAF trial or the overall market acceptance of their products?
In what ways could AtriCure Inc. (Nasdaq: ATRC) leverage the findings from the BoxX-NoAF trial to enhance the company's reputation as a leader in atrial fibrillation treatment?
Considering the prevalence of new-onset atrial fibrillation, how crucial is the success of AtriCure Inc. (ATRC) in the BoxX-NoAF trial for the broader medical community and patient care standards?
**MWN-AI FAQ is based on asking OpenAI questions about AtriCure Inc. (NASDAQ: ATRC).
NASDAQ: ATRC
ATRC Trading
-1.98% G/L:
$29.21 Last:
639,601 Volume:
$29.66 Open:
